Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 3Terminated 2

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 2Genitourinary 2Tumor-Agnostic 1Lymphoid 1Head & Neck 1Gynecologic 1CNS 1

Conditions

Pancreatic Neoplasms 2Ovarian Neoplasms 1Neoplasms 1Head and Neck Neoplasms 1Glioma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Advanced Pancreatic Cancer 1

Interventions

Fluorouracil 616Oxaliplatin 579Gemcitabine 492Capecitabine 445Leucovorin 427Irinotecan 390Bevacizumab 330Cisplatin 320Radiotherapy 245Cetuximab 215Sorafenib 167pembrolizumab 152Docetaxel 150Paclitaxel 140Nivolumab 128Albumin-Bound Paclitaxel 108130-nm albumin-bound paclitaxel 108Folfox protocol 101Panitumumab 95Erlotinib Hydrochloride 95Surgical Procedures, Operative 86regorafenib 84S 1 (combination) 81Drug Therapy 80Radiation 69Carboplatin 65Neoadjuvant Therapy 64Colonoscopy 64Radiosurgery 63Surveys and Questionnaires 60

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × cabiralizumab × Gastrointestinal × Clear all
NCT03697564 2025-08-06

Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer

University of California, San Diego

Phase 2 Completed
2 enrolled 10 charts
Gastrointestinal

Neoplasms, Pancreatic Neoplasms

NCT03336216 2024-07-23

A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer

Bristol-Myers Squibb

Phase 2 Completed
205 enrolled 30 charts
Gastrointestinal

Advanced Pancreatic Cancer

NCT02526017 2022-03-09

FPA008-003

Five Prime Therapeutics, Inc.

Phase 1 Completed
313 enrolled 30 charts
CNSGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Glioma, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡